SAN FRANCISCO, CA--(Marketwired - Jan 11, 2016) - J.P. Morgan 34th Annual Healthcare Conference -- ChemDiv, Inc. of San Diego, CA announced today the achievement of a development milestone in a research and development collaboration initiated in December 2011with Janssen Pharmaceutica NV and Janssen Sciences Ireland UC (formerly Tibotec Pharmaceuticals) of Cork, Ireland, both part of the Janssen Pharmaceutical Companies (Janssen).
During the collaboration, ChemDiv was to identify and develop novel small molecule drug candidates against jointly agreed targets in multiple therapeutic areas using its integrated discovery platforms in San Diego and its Moscow based ChemDiv Research Institute. Progress from the multiyear collaboration with Janssen has led to the selection of a candidate molecule (to an undisclosed target) and ChemDiv is eligible to receive a success milestone.
About ChemDiv and ChemDiv Research Institute:
ChemDiv is a fully integrated discovery and development CRO serving life science industry for 25 successful years . The ChemDiv Research Institute R&D facilities are located at Torrey Pines Center in San Diego, CA, ChemRar High Tech Center and Skolkovo Life Science Cluster in Moscow. ChemDiv accelerates and enables pharma and biotech R&D programs from research concepts to clinic and market registration, covering the complete range of disciplines, in CNS, oncology, inflammation, cardiometabolic, infectious diseases, and other therapeutic area.
